The agreement sets out how the university and AstraZeneca will work together to identify new ways to treat disease and enhance discovery, preclinical and clinical research in a bid to better understand a variety of conditions. Under the agreement, the university and AstraZeneca will exchange staff, share facilities and encourage joint ventures through long-term funded collaborations.
The parties will also focus on enabling technologies such as imaging, informatics and chemistry that have the potential to identify and accelerate drug discovery in a number of different disease areas.
The agreement formalizes previous close contacts between the parties, such as the development of collaborative science networks.
“Teaming up with a company like AstraZeneca will increase our ability to attract the very best researchers, while providing AstraZeneca with access to new technologies, disease models and a large patient research base,” said Professor Alan North, University of Manchester vice president and dean of the faculty of life sciences.